JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
ConclusionsIn HCV GT1- and GT2-infected Japanese patients, treatment with JNJ-4178 was well tolerated and resulted in 100% of patients achieving SVR12.
Authors: Tomita H PMID: 32224558 [PubMed - as supplied by publisher]
The city of Minamata, Japan, is dotted with monuments commemorating victims of an industrial mass poisoning decades ago. High in the hills, a small stone memorial honors other deaths —of cats sacrificed in secret to science. Now, after restudying the ...
David BoazSigns have popped up all over my neighborhood in Arlington, Virginia, urging us to respond to the census – so that the8th wealthiest county in America won ’t miss out on funding collected from taxpayers across the country.Census Bureau materials stress to local officials that census data will help them get “their fair share of funding” from hundreds of federal programs.Obviously this is a zero‐sum game. If my neighbors and I all fill out the form, then you and your neighbors will get less from the common federal trough. But at least we ’ll be getting our “fair sh...
We report the case of an 81-year-old Japanese woman diagnosed with MTX-LPD exhibiting two distinct pathological features from two different sites. Excisional biopsy of the left cervical lymph node revealed EBV-negative diffuse large B-cell lymphoma and biopsy of a pharyngeal ulcer revealed EBV-positive mucocutaneous ulcer. She was treated using an R-CHOP regimen and maintained complete remission for years. This case demonstrates the heterogeneous pathology of MTX-LPD and suggests the necessity of multiple biopsy. PMID: 32224560 [PubMed - in process]
(Japan Science and Technology Agency) JST has announced a success of the development subject 'Manufacturing Technology for New Plant-Origin Functional Materials' in developing a refining facility that reduces manufacturing cost of the Eucommia elastomer to approximately one-eighth of the cost at the beginning of the project and producing 10 tons of Eucommia elastomer per year highly efficiently with an extraction purity of 99.8%.
(Tokyo University of Agriculture and Technology) A research team led by scientists from Tokyo University of Agriculture and Technology (TUAT), Japan, has successfully established 3D cultured tissue that mimics liver fibrosis, a key characteristic of non-alcoholic steatohepatitis (NASH). For making the 3D culture, cells were collected from liver tissues of NASH model mice. Their findings open up a new avenue for developing drugs for NASH patients, identifying new markers for early diagnosis, and better understanding the disease progression.
Contributor : Masashi KurodaSeries Type : Expression profiling by arrayOrganism : Mus musculusTo identify the genes that are regulated by IRF7, we have performed DNA microarray in 3T3-L1 adipocytes differentiated from precursor cells infected with retrovirus empty or carrying IRF7. Plasmids (Empty- and IRF7-pMSCV) were kindly provided from Dr. Eguchi at the Okayama University Graduate School of Medicine, Okayama, Japan [Cell Metab. 2008;7: 86-94.]. Infected 3T3-L1 preadipocytes were selected by puromycin treatment and differentiated into adipocytes. 7 days after the induction of adipogenesis, total RNA was isolated.
Contributors : Christine Yu ; Kaoru Hida ; Efstathia PapafragkouSeries Type : Expression profiling by genome tiling arrayOrganism : Allium fistulosum ; Apium graveolens ; Astrovirus sp. ; Bacillus subtilis ; Coxsackievirus ; Hepatitis E virus ; Hepatovirus A ; Norovirus ; Rotavirus ; Sapovirus ; Solanum lycopersicum ; unidentified adenovirusThe capability of the U.S. Food and Drug Administration Enteric Viruses tiling microarray (FDA-EVIR) was assessed for rapid molecular identification of human norovirus (NoV) and hepatitis A virus (HAV) extracted from artificially inoculated fresh produce. Two published viral extraction ...
Fujifilm announced Tuesday that it's beginning phase III trials for its flu drug, Avigan, in coronavirus patients in Japan. It interferes with flu's ability to replicate, and may for COVID-19 too.
Conclusions. In Japan, where>70% of retransplantations are performed using living donors, the indications and timing are different from those in previous reports from other countries, while maintaining comparable survival rates. Considering technical challenges, graft failure within 365 days should be thoroughly restricted to justify the use of living donor.